Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes
N Engl J Med
.
2022 Feb 17;386(7):e17.
doi: 10.1056/NEJMc2114590.
Authors
Dimitrios Patoulias
1
,
Christodoulos Papadopoulos
1
,
Michael Doumas
1
Affiliation
1
Aristotle University of Thessaloniki, Thessaloniki, Greece dipatoulias@gmail.com.
PMID:
35172065
DOI:
10.1056/NEJMc2114590
No abstract available
Publication types
Letter
Comment
MeSH terms
Diabetes Mellitus, Type 2* / drug therapy
Gastric Inhibitory Polypeptide
Glucagon-Like Peptides / adverse effects
Humans
Substances
semaglutide
Gastric Inhibitory Polypeptide
Glucagon-Like Peptides
tirzepatide